优化成人急性淋巴细胞白血病的前期治疗:向免疫治疗的范式转变
Amr Hanbali1, Mostafa Saleh2, Mohamed Kharfan-Dabaja3
1King Faisal Specialist Hospital and Research Center, Riyadh, KSA, 11211, USA. ahanbali@kfshrc.edu.sa.
Medical oncology (Northwood, London, England)
|October 22, 2025
概括
前线急性淋巴细胞白血病 (ALL) 治疗现在整合了向免疫疗法,提高了缓解率和降低毒性. 新的组合增强了各种ALL亚型的结果,包括费城染色体阳性和T细胞ALL.
科学领域:
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 成年急性淋巴细胞白血病 (ALL) 治疗正在随着向免疫治疗剂的整合而演变为前线治疗.
- 传统的化疗方案正在被新药增强,以提高缓解率和最小残留疾病 (MRD) 的负面影响,同时降低毒性.
研究的目的:
- 审查成人ALL不断发展的治疗方案,重点是纳入向免疫疗法.
- 为了突出特定免疫治疗剂的疗效,如blinatumomab,inotuzumab ozogamicin (InO),rituximab和nelarabine在各种ALL亚型中.
- 讨论MRD测试和基因组分析对个性化治疗策略的影响.
主要方法:
- 对成人ALL治疗方案的当前文献和临床试验数据的综述.
- 针对性免疫疗法 (blinatumomab,InO,rituximab,nelarabine) 纳入前线和高风险ALL治疗方案的分析.
- 检查MRD测试和基因组分析在指导个性化治疗中的作用.
主要成果:
- 布莱纳托马布纳入前线协议导致费城染色体阴性 (Ph-) 和阳性 (Ph+) 的ALL早期消除MRD.
- 在otuzumab ozogamicin (InO) 越来越多地用于老年或医疗不适合的患者.
- 添加利图西马布可以改善CD20阳性B-ALL的长期结果,而内拉拉宾可以降低T细胞ALL中中枢神经系统复发的风险.
- 高风险的ALL亚型,包括Ph+和Ph类ALL,从免疫治疗和分子向治疗中受益.
- 基因组分析和MRD测试可以实现个性化的治疗策略.
结论:
- 成年ALL的最前线治疗越来越多地结合了向免疫疗法,从而改善了结果并降低了毒性.
- 基于MRD和基因组分析的个性化治疗策略正在彻底改变ALL护理.
- 目前正在进行的临床试验旨在优化向疗法和CAR T细胞疗法的序列,以改善存活率并减少对干细胞移植的依赖.
更多相关视频
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15.8K
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.7K
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
